Perianal fistulae in Crohn's disease: Current and future approaches to treatment

Inflammatory Bowel Diseases

Volumn 16, Issue 5, 2010, Pages 870-880

  Keshaw, Hussila ^a   Foong, Keen S ^a   Forbes, Alastair ^a   Day, Richard M ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Biomaterials; Crohn's disease; Perianal fistula; Therapy

Indexed keywords

ADALIMUMAB; ADHESIVE AGENT; AZATHIOPRINE; BIOMATERIAL; CEFTAZIDIME; CERTOLIZUMAB PEGOL; CIPROFLOXACIN; COLLAGEN; CYCLOSPORIN; FIBRIN GLUE; HYALURONIC ACID; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; METRONIDAZOLE; MICROSPHERE; POLYGLACTIN; PREDNISOLONE; TACROLIMUS;

ABSENCE OF SIDE EFFECTS; ANTIBIOTIC THERAPY; ANTIBODY PRODUCTION; ANUS FISTULA; AUTOLOGOUS STEM CELL TRANSPLANTATION; CELL THERAPY; CLINICAL TRIAL; COMORBIDITY; CROHN DISEASE; DRUG BIOAVAILABILITY; DRUG COST; DRUG MECHANISM; DRUG RELEASE; FECES INCONTINENCE; FIBROBLAST; FISTULECTOMY; FISTULOTOMY; GLOSSITIS; HEALING IMPAIRMENT; HUMAN; ILEOSTOMY; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; METALLIC TASTE; NAUSEA; PAIN; PERIANAL ABSCESS; PERIPHERAL NEUROPATHY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROCTOCOLECTOMY; RECTUM RESECTION; RECURRENT DISEASE; REVIEW; SIDE EFFECT; SUPPURATION; SURGICAL APPROACH; SURGICAL TECHNIQUE; TASTE DISORDER; TISSUE ENGINEERING; UNSPECIFIED SIDE EFFECT;

ANTI-BACTERIAL AGENTS; CROHN DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; RECTAL FISTULA;

EID: 77950645806     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21137     Document Type: Review

References (143)

1. Morris J, Spencer JA, Ambrose NS. MR imaging classification of perianal fistulas and its implications for patient management. Radiographics. 2000;20:623-635.
2. Sainio P. Fistula-in-ano in a defined population. Incidence and epidemiological aspects. Ann Chir Gynaecol. 1984;73:219-224.
3. Serour F, Somekh E, Gorenstein A. Perianal abscess and fistulain-ano in infants: a different entity? Dis Colon Rectum. 2005;48: 359-364.
4. Zanotti C, Martinez-Puente C, Pascual. I, et al. Smoking affects the outcome of transanal mucosal advancement flap repair of transsphincteric fistulas. Br J Surg. 2003;90:351-354.
5. Schwartz DA, Pemberton JH, Sandborn WJ. Diagnosis and treatment of perianal fistulas in Crohn disease. Ann Intern Med. 2001;135: 906-918.
6. Hughes LE. Surgical pathology and management of anorectal Crohn's disease. J R Soc Med. .1978;71:644-651,
7. Parks AG. Pathogenesis and treatment of fistula-in-ano. Br Med J. 1961;1:463-469.
8. Schuppan D, Freitag T. Fistulising Crohn's disease: MMPs gone awry. Gut. 2004;53:622-624.
9. West RL, Van der Woude CJ, Endtz HP, et al. Perianal fistulas in Crohn's disease are predominantly colonized by skin flora: implications for antibiotic treatment? Dig Dis Sci, 2005;50:1260-1263.
10. Bernstein LH, Frank MS, Brandt LJ, et al. Healing of perineal Crohn's disease with metronidazole. Gastroenterology. 1980;79: 357-365.
11. Schneider MU, Strobel S, Riemann JF, et al. Treatment of Crohn's disease with metronidazole. Dtsch Med Wochenschr. 1981;106: 1126-1129.
12. Jakobovits J, Schuster MM. Metronidazole therapy for Crohn's disease and associated fistulae. Am J Gastroenterol. 1984;79:533-540. (Pubitemid 14091511)
13. Schneider MU, Laudage G, Guggenmoos-Holzmann I, et al. Metronidazole in the treatment of Crohn disease. Results of a controlled randomized prospective study. Dtsch Med Wochenschr. 1985;.110: 1724-1730.
14. Brandt LJ, Bernstein LH, Boley SJ, et al. Metronidazole therapy for perineal Crohn's disease: a follow-up study. Gastroenterology. 1982; 83:383-387.
15. Peppercorn MA. Is there a role for antibiotics as primary therapy in Crohn's ileitis? J Clin Gastroenterol. 1993;17:235-237.
16. Stokkers PC, Camoglio L, van Deventer SJ. Tumor necrosis factor (TNF) in inflammatory bowel disease: gene polymorphisms, animal models, and potential for anti-TNF therapy. J Inflamm. 1995;47: 97-103. (Pubitemid 26376208)
17. Breese EJ, Michie CA, Nicholls SW, et al. Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology. 1994;106:1455-1466.
18. Schreiber S, Nikolaus S, Hampe J, et al. Tumour necrosis factor alpha and interleukin 1beta in relapse of Crohn's disease. Lancet. 1999;353:459-461.
19. Sandborn WJ. Clinical perspectives in Crohn's disease. Moving forward with anti-TNF-alpha therapy: current needs and future treatments. Rev Gastroenterol Disord. 2007;7(suppl 2):S23-S35.
20. Reinecker HC, Steffen M, Witthoeft T, et al. Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol. 1993;94:174-181. (Pubitemid 23308385)
21. Rutgeerts P, Van. AG, Vermeire S. Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology. 2004;126:1593-1610. (Pubitemid 38649876)
22. Di Sabatino A, Pender SL, Jackson CL, et al. Functional modulation of Crohn's disease myofibroblasts by anti-tumor necrosis factor antibodies. Gastroenterology. 2007;133:137-149.
23. McCabe RP. A multicenter trial of cA2 anti-TNF chimeric monoclonal antibody in patients with active Crohn's disease. Gastroenterology. 1996;110(suppl):A962.
24. van Dullemen HM, van Deventer SJ, Hommes DW, et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology. 1995;109:129-135.
25. Targan SR, Hanauer SB, S van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med. 1997;337:1029-1035.
26. Rutgeerts PD. Retreatment with anti-TNF-a chimeric antibody (cA2) effectively maintains cA2-induced remission in Crohn's disease. Gastroenterology. 1997;112(suppl):A1078.
27. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002;359:1541-1549. (Pubitemid 34621118)
28. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med. 1999;340: 1398-1405. (Pubitemid 29205403)
29. Van AG, Vanbeckevoort D, Bielen D, et al. Magnetic resonance imaging of the effects of infliximab on perianal fistulizing Crohn's disease. Am J Gastroenterol. 2003;98:332-339.
30. Bell SJ, Halligan S, Windsor AC, et al. Response of fistulating Crohn's disease to infliximab treatment assessed by magnetic resonance imaging. Aliment Pharmacol Ther. 2003;17:387-393. (Pubitemid 36259401)
31. van Bodegraven AA, Sloots CE, Felt-Bersma RJ, et al. Endosonographic evidence of persistence of Crohn's disease-associated fistulas after infliximab treatment, irrespective of clinical response. Dis Colon Rectum. 2002;45:39-45.
32. Ardizzone S, Maconi G, Colombo E, et al. Perianal fistulae following infliximab treatment: clinical and endosonographic outcome. Inflamm Bowel Dis. 2004;10:91-96.
33. Sands BE, Blank MA, Patel K, et al. Long-term treatment of rectovaginal fistulas in Crohn's disease: response to infliximab in the ACCENT II Study. Clin Gastroenterol Hepatol. 2004;2:91.2-920.
34. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med. 2003;348:601-608. (Pubitemid 36204954)
35. Hanauer SB, Wagner CL, Bala M, et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol. 2004;2:542-553.
36. Lichtenstein GR. Incorrect cost of infliximab in fistulizing Crohn's disease. Gastroenterology. 2004;127:691-692.
37. Stratakos G, Kalomenidis I, Papas V, et al. Cough and fever in a female with Crohn's disease receiving infliximab. Eur Respir J. 2005;26:354-357.
38. Han PD, Cohen RD. Managing immunogenic responses to infliximab: treatment implications for patients with Crohn's disease. Drugs. 2004;64:1767-1777.
39. Ahmad NM, Ahmad KM, Younus F. Severe adenovirus pneumonia (AVP) following infliximab infusion for the treatment of Crohn's disease. J Infect. 2007;54:29-32.
40. Aberra FN, Stettler N, Brensinger C, et al. Risk for active tuberculosis in inflammatory bowel disease patients. Clin Gastroenterol Hepatol. 2007;5:1070-1075.
41. Bickston SJ, Lichtenstein GR, Arseneau KO, et al. The relationship between infliximab treatment and lymphoma in Crohn's disease. Gastroenterology. 1999;117:1433-1437.
42. Keane J, Gershon S, Wise, RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001;345:1098-1104.
43. Lichtiger SI. Healing of perianal fistulae by local injection of antibody to TNF. Gastroenterology. 2008;120(suppl):A3154.
44. Poggioli G, Laureti S, Pierangeli F, et al. Local injection of Infliximab for the treatment of perianal Crohn's disease. Dis Colon Rectum. 2005;48:768-774.
45. Topstad DR, Panaccione R, Heine JA, et al. Combined seton placement, infliximab infusion, and maintenance immunosuppressives improve healing rate in fistulizing anorectal Crohn's disease: a single center experience. Dis Colon Rectum. 2003;46:577-583.
46. Regueiro M, Mardini H. Treatment of perianal fistulizing Crohn's disease with infliximab alone or as an adjunct to exam under anesthesia with seton placement. Inflamm Bowel Dis. 2003;9:98-103. (Pubitemid 36367318)
47. Hyder SA, Travis SP, Jewell DP, et al. Fistulating anal Crohn's disease: results of combined surgical and infliximab treatment. Dis Colon Rectum. 2006;49:1837-1841.
48. Sandborn WJ, Present DH, Isaacs KL, et al. Tacrolimus for the treatment of fistulas in patients with Crohn's disease: a randomized, placebo-controlled trial. Gastroenterology. 2003;125:380-388.
49. Hart AL, Plamondon S, Kamm MA. Topical tacrolimus in the treatment of perianal Crohn's disease: exploratory randomized controlled trial. Inflamm Bowel Dis. 2007;13:245-253. (Pubitemid 46465904)
50. Hanauer SB, Smith MB. Rapid closure of Crohn's disease fistulas with continuous intravenous cyclosporin A. Am J Gastroenterol. 1993;88:646-649.
51. Randhawa PS, Shapiro R, Jordan ML, et al. The histopathological changes associated with allograft rejection and drug toxicity in renal transplant recipients maintained on FK506. Clinical significance and comparison with cyclosporine. Am J Surg Pathol. 1993;17:60-68. (Pubitemid 23011321)
52. Lowry PW, Weaver AL, Tremaine WJ, et al. Combination therapy with oral tacrolimus (FK506) and azathioprine or 6-mercaptopurine for treatment-refractory Crohn's disease perianal fistulae. Inflamm Bowel Dis. 1999;5:239-245.
53. Present D, Lichtiger SL. Efficacy of cyclosporine in treatment of fistula of Crohn's disease. Dig Dis Sci. 1994;39:374-380. (Pubitemid 24073614)
54. Hinterleitner TA, Petritsch W, Aichbichler B, et al. Combination of cyclosporine, azathioprine and prednisolone for perianal fistulas in Crohn's disease. Z Gastroenterol. 1997;35:603-608.
55. Ochsenkuhn T, Goke B, Sackmann M. Combining infliximab with 6mercaptopurine/azafhioprine for fistula therapy in Crohn's disease. Am J Gastroenterol. 2002;97:2022-2025.
56. Ho YH, Tan M, Leong AF, et al. Marsupialization of fistulotomy wounds improves healing: a randomized controlled trial. Br J Surg. 1998;85:105-107. (Pubitemid 28034124)
57. Pescatori M, Ayabaca Sm, Cafaro D, et al. Marsupialization of fistulotomy and fistulectomy wounds improves healing and decreases bleeding: a randomized controlled trial. Colorectal Dis. 2006;8:11-14.
58. Finlay I. Objectives in management. In: Phillips RKS, Lunniss PJ, eds. Anal Fistula: Surgical Evaluation and Management. London: Chapman & Hall; 1996:69-72.
59. Williams JG, MacLeod CA, Rothenberger DA, et al. Seton treatment of high anal fistulae. Br J Surg. 1991;78:1159-1161.
60. Faucheron JL, Saint-Marc O, Guibert L, et al. Long-term seton drainage for high anal fistulas in Crohn's disease-a sphincter-saving operation? Dis Colon Rectum. 1996;39:208-211. (Pubitemid 26050901)
61. Lunniss PJ, Kamm MA, Phillips RK. Factors affecting continence after surgery for anal fistula. Br J Surg. 1994;81:1382-1385.
62. Parks AG, Stitz RW. The treatment of high fistula-in-ano. Dis Colon Rectum. 1976;19:487-499.
63. Kennedy HL, Zegarra JP. Fistulotomy without external sphincter division for high anal fistulae. Br J Surg. 1990;77:898-901,
64. Van Tets WF, Kuijpers JH. Seton treatment of perianal fistula with high anal or rectal opening. Br J Surg. 1995;82:895-897.
65. McCourtney JS, Finlay IG. Cutting seton without preliminary internal sphincterotomy in management of complex high fistula-in-ano. Dis Colon Rectum. 1996;39:55-58.
66. Elting AW. The treatment of fistula in ano: with especial reference to the Whitehead operation. Ann Surg. 1912;56:744-752.
67. Kodner IJ, Mazor A, Shemesh EI, et al. Endorectal advancement flap repair of rectovaginal and other complicated anorectal fistulas. Surgery. 1993;114:682-689.
68. Mizrahi N, Wexner SD, Zmora O, et al. Endorectal advancement flap: are there predictors of failure? Dis Colon Rectum. 2002;45:1616-1621. (Pubitemid 35471011)
69. Sonoda T, Hull T, Piedmonte MR, et al. Outcomes of primary repair of anorectal and rectovaginal fistulas using the endorectal advancement flap. Dis Colon Rectum. 2002;45:1622-1628. (Pubitemid 35471012)
70. Zimmerman DD, Delemarre JB, Gosselink MP, et al. Smoking affects the outcome of transanal mucosal advancement flap repair of trans-sphincteric fistulas. Br J Surg. 2003;90:351-354.
71. Ortiz H, Marzo J. Endorectal flap advancement repair and fistulectomy for high trans-sphincteric and suprasphincteric fistulas. Br J Surg. 2000;87:1680-1683.
72. Gustafsson UM, Graf W. Excision of anal fistula with closure of the internal opening: functional and manometric results. Dis Colon Rectum. 2002;45:1672-1678. (Pubitemid 35471020)
73. Kuypers HC. Use of the seton in the treatment of extrasphincteric anal fistula. Dis Colon Rectum. 1984;27:109-110. (Pubitemid 14176307)
74. Wolff BG, Gulp CE, Beart RW, et al. Anorectal Crohn's disease. A long-term perspective. Dis Colon Rectum. 1985;28:709-711. (Pubitemid 16236872)
75. Levien DH, Surrell J, Mazier WP. Surgical treatment of anorectal fistula in patients with Crohn's disease. Surg Gynecol Obstet. 1989; 169:133-136. (Pubitemid 19200145)
76. Williams JG, Rothenberger DA, Nemer FD, et al. Fistula-in-ano in Crohn's disease. Results of aggressive surgical treatment. Dis Colon Rectum. 1991;34:378-384.
77. Koelbel G, Schmiedl U, Majer MC, et al. Diagnosis of fistulae and sinus tracts in patients with Crohn disease: value of MR imaging. AJR Am J Roentgenol. 1989;152:999-1003. (Pubitemid 19125130)
78. Sygut A, Zajdel R, Kedzia-Budziewska R, et al. Late results of treatment of anal fistulas. Colorectal Dis. 2007;9:151-158. (Pubitemid 46111599)
79. Poritz LS, Rowe WA, Koltun WA. Remicade does not abolish the need for surgery in fistulizing Crohn's disease. Dis Colon Rectum. 2002;45:771-775.
80. Gaertner WB, Decanini A, Mellgren A, et al. Does infliximab infusion impact results of operative treatment for Crohn's perianal fistulas? Dis Colon Rectum. 2007;50:1754-1760. (Pubitemid 350077116)
81. Feagan BG, Vreeland MG, Larson LR, et al. Annual cost of care for Crohn's disease: a payor perspective. Am J Gastroenterol. 2000;95: 1955-1960.
82. Becker JC, Domschke W, Pohle T. Biological in vitro effects of fibrin glue: fibroblast proliferation, expression and binding of growth factors. Scand J Gastroenterol. 2004;39:927-932.
83. Saed GM, Kruger M, Diamond MP. Expression of transforming growth factor-beta and extracellular matrix by human peritoneal mesothelial cells and by fibroblasts from, normal peritoneum and adhesions: effect of Tisseel. Wound Repair Regen. 2004;12:557-564.
84. Cintron JR, Park JJ, Orsay CP, et al. Repair of fistulas-in-ano using fibrin adhesive: long-term follow-up. Dis Colon Rectum. 2000;43:944-949.
85. Siedentop KH, Chung SE, Park. JJ, et al. Evaluation of pooled fibrin sealant for ear surgery. Am J Otol. 1997;18:660-664.
86. Hjortrup A, Moesgaard F, Kjaergard J. Fibrin adhesive in the treatment of perineal fistulas. Dis Colon. Rectum. 1991;34:752-754.
87. Abel ME, Chiu YS, Russell TR, et al. Autologous fibrin glue in the treatment of rectovaginal and complex fistulas. Dis Colon Rectum. 1993;36:447-449.
88. Venkatesh KS, Ramanujam P. Fibrin glue application in the treatment of recurrent anorectal fistulas. Dis Colon Rectum. 1999;42: 1136-1139.
89. Patrlj L, Kocman B, Martinac M, et al. Fibrin glue-antibiotic mixture in the treatment of anal fistulae: experience with 69 cases. Dig Surg. 2000;17:77-80.
90. Sentovich SM. Fibrin glue for all anal fistulas. J Gastrointest Surg. 2001;5:158-161.
91. Lindsey I, Smilgin-Humphreys MM, Cunningham C, et al. A randomized, controlled trial of fibrin glue vs. conventional treatment for anal fistula. Dis Colon Rectum. 2002;45:1608-1615.
92. Aitola P, Hiltunen KM, Matikainen M. Fibrin glue in perianal fistulas-a pilot study. Ann Chir Gynaecol. 1999;88:136-138.
93. Maralcan G, Baskonus I, Aybasti N, et al. The use of fibrin glue in the treatment of fistula-in-ano: a prospective study. Surg Today. 2006;36:166-170.
94. Sentovich SM. Fibrin glue for anal fistulas: long-term results. Dis Colon. Rectum. 2003;46:498-502.
95. Loungnarath R, Dietz DW, Mutch MG, et al. Fibrin glue treatment of complex anal fistulas has low success rate. Dis Colon Rectum. 2004;47:432-436.
96. Park JJ, Cintron JR, Orsay CP, et al. Repair of chronic anorectal fistulae using commercial fibrin sealant. Arch Surg. 2000;135:166-169. (Pubitemid 30078469)
97. Singer M, Cintron J, Nelson R, et al. Treatment of fistulas-in-ano with fibrin sealant in combination with intra-adhesive antibiotics and/ or surgical closure of the internal fistula opening. Dis Colon Rectum. 2005;48:799-808.
98. Vitton V, Gasmi M, Barthet M, et al. Long-term healing of Crohn's anal fistulas with fibrin glue injection. Aliment Pharmacol. Ther. 2005;21:1453-1457. (Pubitemid 40874162)
99. Zmora O, Mizrahi N, Rotholtz N, et al. Fibrin glue sealing in the treatment of perineal fistulas. Dis Colon Rectum. 2003;46:584-589.
100. Ellis CN, Clark S. Fibrin glue as an adjunct to flap repair of anal fistulas: a randomized, controlled study. Dis Colon Rectum. 2006;49: 1736-1740. (Pubitemid 44800491)
101. Currie LJ, Sharpe JR, Martin R. use of fibrin glue in skin grafts and tissue-engineered skin replacements: a review. Plast Reconstr Surg. 2001;108:1713-1726.
102. Hammond TM, Lunniss PJ. Novel biomaterials in the management of anal fistulas. Dis Colon Rectum. 2006;49:1463-1464.
103. Vasilevsky CA, Gordon PH. The incidence of recurrent abscesses or fistula-in-ano following anorectal suppuration. Dis Colon Rectum. 1984;27:126-130.
104. Garcia-Aguilar J, Belmonte C, Wong WD, et al. Anal fistula surgery. Factors associated with recurrence and incontinence. Dis Colon Rectum. 1996;39:723-729. (Pubitemid 26243964)
105. Abcarian H, Dodi G, Girona J, et al. Fistula-in-ano. Int J Colorectal Dis. 1987;2:51-71,
106. Lunniss PJ, Sheffield JP, Talbot IC, et al. Persistence of idiopathic anal fistula may be related to epithelialization Br J Surg. 1995;82: 32-33.
107. Cintron JR, Park JJ, Orsay CP, et al. Repair of fistulas-in-ano using autologous fibrin tissue adhesive. Dis Colon Rectum. 1999;42: 607-613. (Pubitemid 29228405)
108. Gisbertz SS, Sosef MN, Festen S, et al. Treatment of fistulas in ano with fibrin glue. Dig Surg. 2005;22:91-94. (Pubitemid 40754698)
109. Buchanan GN, Bartram CI, Phillips RK, et al. Efficacy of fibrin sealant in the management of complex anal fistula: a prospective trial. Dis Colon Rectum. 2003;46:1167-1174.
110. Hammond TM, Grahn MF, Lunniss PJ. Fibrin glue in the management of anal fistulae. Colorectal Dis. 2004;6:308-319.
111. Beierlein W, Scheule AM, Antoniadis G, et al. An immediate, allergic skin reaction to aprotinin after reexposure to fibrin sealant. Transfusion. 2000;40:302-305. (Pubitemid 30171679)
112. Berguer R, Staerkel RL, Moore EE, et al. Warning: fatal reaction to the use of fibrin glue in deep hepatic wounds. Case reports. J Trauma. 1991;31:408-411.
113. de la Portilla F, Rada R, Leon E, et al. Evaluation of the use of BioGlue in the treatment of high anal fistulas: preliminary results of a pilot study. Dis Colon Rectum. 2007;50:218-222. (Pubitemid 46227219)
114. Abbas MA, Tejirian T. Bioglue for the treatment of anal fistula is associated with acute anal sepsis. Dis Colon Rectum. 2008;51:1155.
115. Alexander SM, Mitalas LE, Gosselink MP, et al. Obliteration of the fistulous tract with BioGlue(R) adversely affects the outcome of transanal advancement flap repair. Tech. Coloproctol. 2008;12:225-228.
116. LeMaire SA, Schmittling ZC, Coselli JS, et al. BioGlue surgical adhesive impairs aortic growth and causes anastomotic strictures. Ann Thorac Surg. 2002;73:1500-1505.
117. Erasmi AW, Sievers HH, Wolschlager C. Inflammatory response after BioGlue application. Ann Thorac Surg. 2002;73:1025-1026.
118. Klimo P, Khalil A, Slotkin JR, et al. Wound complications associated with the use of bovine serum albumin-glutaraldehyde surgical adhesive in pediatric patients. Neurosurgery. 2007;60:305-309.
119. Furst W, Banerjee A. Release of glutaraldehyde from an albuminglutaraldehyde tissue adhesive causes significant in vitro and in vivo toxicity. Ann Thorac Surg. 2005;79:1522-1528.
120. Shaker MA, Hindy AM, Mounir RM, et al. Competent closure of chronic oroantral fistula with Zenoderm. Egypt Dent J. 1995;41: 1237-1242.
121. Shelton AA, Welton ML. Transperineal repair of persistent rectovaginal fistulas using an acellular cadaveric dermal graft (AlloDerm). Dis Colon Rectum. 2006;49:1454-1457.
122. Cole P, Horn TW, Thaller S. The use of decellularized dermal grafting (AlloDerm) in persistent oro-nasal fistulas after tertiary cleft palate repair. J Craniofac Surg. 2006; 17:636-641.
123. Himpson RC, Cohen CR, Sibbons P, et al. Histological evidence for enhanced anal fistula repair using autologous fibroblasts in a dermal collagen matrix. Comp Clin Pathol. 2007;16:9-14.
124. Schultz DJ, Brasel KJ, Spinelli KS, et al. Porcine small intestine submucosa as a treatment for enterocutaneous fistulas. J Am Coll Surg. 2002;194:541-543.
125. Keckler SJ, Spilde TL, St Peter SD, et al. Treatment of bronchopleural fistula with small int6stinal mucosa and fibrin glue sealant. Ann Thorac Surg. 2007;84:1383-1386.
126. Johnson EK, Gaw JU, Armstrong DN. Efficacy of anal fistula plug vs. fibrin glue in closure of anorectal fistulas. Dis Colon Rectum. 2006;49:371-376.
127. Ellis CN. Bioprosthetic plugs for complex anal fistulas: an early experience. J Surg Educ. 2007;64:36-40.
128. Lawes DA, Efron JE, Abbas M, et al. Early experience with the bioabsorbable anal fistula plug. World J Surg. 2008;32:1157-1159.
129. Christoforidis D, Etzioni DA, Goldberg SM, et al. Treatment of complex anal fistulas with the collagen fistula plug. Dis Colon Rectum. 2008;51:1482-1487.
130. Champagne BJ, O'Connor LM, Ferguson M, et al. Efficacy of anal fistula plug in closure of cryptoglandular fistulas; long-term followup. Dis Colon Rectum. 2006;49:1817-1821. (Pubitemid 44853437)
131. van Koperen PJ, Hoore AD, Wolthuis AM, et al. Anal fistula plug for closure of difficult anorectal fistula: a prospective study. Dis Colon Rectum. 2007;50:2168-2172.
132. O'Connor L, Champagne BJ, Ferguson MA, et al. Efficacy of anal fistula plug in closure of Crohn's anorectal fistulas. Dis Colon Rectum. 2006;49:1569-1573.
133. Ky AJ, Sylla P, Steinhagen R, et al. Collagen fistula plug for the treatment of anal fistulas. Dis Colon Rectum. 2008;51:838-843.
134. Schwandner O, Stadler F, Dietl O, et al. Initial experience on efficacy in closure of cryptoglandular and Crohn's transsphincteric fistulas by the use of the anal. fistula plug. Int J Colorectal Dis. 2008;23: 319-324.
135. Garg P. To determine the efficacy of anal fistula plug in the treatment of high fistula-in-ano-an initial experience. Colorectal Dis. 2009;11:588-591,
136. Ueno T, Pickett LC, de la Fuente SG, et al. Clinical application of porcine small intestinal submucosa in the management of infected or potentially contaminated abdominal defects. J Gastrointest Surg. 2004;8:109-112.
137. Franklin ME, Gonzalez JJ, Glass JL. Use of porcine small intestinal submucosa as a prosthetic device for laparoscopic repair of hernias in contaminated fields: 2-year follow-up. Hernia. 2004;8:186-189.
138. Helton WS, Fisichella PM, Berger R, et al. Short-term outcomes with small intestinal submucosa for ventral abdominal hernia. Arch Surg. 2005;140:549-560.
139. Kirkegaard T, Hansen A, Bruun E, et al. Expression and localisation of matrix metalloproteinases and their natural inhibitors in fistulae of patients with Crohn's disease. Gut. 2004;53:701-709.
140. Ascanelli S, de Tullio D, Gregorio C, et al. Autologous fibroblasts transplant after infliximab administration: a new approach in Crohn's perianal. fistulas? Brief clinical report. Int J Colorectal. Dis. 2007;22: 1135-1136.
141. Garcia-Olmo D, Garcia-Arranz M, Herreros D. Expanded adiposederived stem cells for the treatment of complex perianal fistula including Crohn's disease. Expert Opin Biol Ther. 2008;9: 1417-1423.
142. Garcia-Olmo D, Herreros D, Pascual I, et al. Expanded adiposederived stem cells for the treatment of complex perianal fistula: a phase II clinical trial. Dis Colon Rectum. 2009;52:79-86.
143. Blaker JJ, Pratten J, Ready D, et al. Assessment of antimicrobial microspheres as a prospective novel treatment targeted towards the repair of perianal fistulae. Aliment Pharmacol Ther. 2008;28: 614-622.